1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Novavax, Inc.

Novavax, Inc.

NVAX
Novavax, Inc.US flagNASDAQ Global Select
10.67
USD
-0.15
- -
1.76BMarket Cap
Novavax, Inc.
NVAX
(NASDAQ Global Select)

Recent

price

10.67

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.07
2.59
3.35
2.47
2.72
2.76
1.13
2.13
1.85
0.77
0.39
2.66
20.45
5.52
4.48
6.94
2.54
Revenue per Share
-6.82
-3.41
-4.33
-6.13
-7.35
-11.97
-20.68
-12.56
-9.99
-5.51
-7.27
-23.44
-8.42
-5.41
-1.23
2.72
-1.52
Basic EPS, GAAP
-6.27
-4.16
-2.77
-5.35
-5.93
-9.62
-19.11
-9.87
-10
-5.67
-0.74
4.3
-5.37
-7.09
-0.57
-1.51
-0.23
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
10.64
9.2
10.85
19.48
19.23
21.68
-0.41
-6.29
-8.74
-5.75
8.84
-4.64
-7.37
-5.14
-3.89
-0.79
-1.16
Book Value per Share
4.67
3.54
6.37
12.3
13.6
16.95
-4.9
-10.1
-11.78
-7.5
6.85
-6.37
-8.84
-6.05
-4.56
-1.48
-1.84
Tangible Book Value per Share
5
6
7
8
11
13
14
15
18
24
58
74
78
101
152
162
163
Basic Weighted Avg Shares
- -
15
22
21
31
36
15
31
34
19
22
198
1,599
556
682
1,123
414
Sales/Revenue/Turnover
-11,222.74
-146.92
-134.38
-250.7
-272.97
-433.75
-1,752.84
-550.78
-507.23
-694.44
-1,861.35
-853.61
-40.32
-101.82
-36.49
49.01
-32.93
Operating Margin (%)
1
2
2
3
4
6
9
10
8
6
5
13
29
41
48
28
18
Depreciation Expense
-36
-19
-29
-52
-83
-157
-280
-184
-185
-133
-418
-1,744
-658
-545
-187
440
-248
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.42
2.1
Effective Tax Rate (%)
-10,410.5
-131.84
-129.13
-248.54
-270.55
-432.93
-1,823.53
-589.46
-538.81
-711.04
-1,868.23
-882.55
-41.15
-97.97
-27.49
39.19
-59.87
Profit Margin (%)
23
19
39
127
154
211
221
130
74
71
669
-235
-757
-491
-25
518
441
Working Capital
- -
- -
1
1
- -
- -
316
318
319
321
362
323
198
224
223
246
293
LT Debt
59
54
80
203
230
293
-6
-102
-168
-186
627
-352
-634
-717
-624
-128
-191
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-402.64
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-339.81
-241.7
Return on Capital (%)
-55.36
-34.3
-42.52
-36.68
-38.33
-60.1
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
3
2
4
LT Borrowings
244
291
291
LT Finance Leases
2
2
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
163
164
165
Market Capitalization
1,093
1,338
1,553

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
978
851
771
Cash, Cash Equivalents & STI
735
790
719
Accounts Receivable, Net
106
23
19
Inventories
12
11
10
Total Current Liabilities
460
342
331
Payables & Accruals
81
119
104
ST Debt
3
2
4
Deferred Revenue
140
89
87

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
111.59%
-31.04%
-79.52%
Free Cash Flow
-92.4%
-183.62%
180.34%
Net Income, GAAP
6.86%
-32.59%
-334.83%
Sales/Revenue/Turnover
154.37%
302.78%
64.69%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
94
415
85
88
682
2025
667
239
70
147
1,123
2026
140
57
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-1.05
1.09
-0.76
-0.51
-1.23
2025
3.22
0.66
-1.25
0.11
2.72
2026
-0.06
-0.32
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
OncoCyte Corporation (OCX)
Yantai Zhenghai Biotechnology Co., Ltd. (300653.SZ)
Idorsia Ltd (0RQE.L)
argenx SE (ARGNF)
Chemomab Therapeutics Ltd. (CMMB)
Otonomy, Inc. (OTIC)
Business
Novavax, Inc., a biotechnology enterprise, dedicates itself to the research, advancement, and market introduction of vaccines aimed at preventing significant infectious illnesses. The company's lead commercial offering, Nuvaxovid, is a protein-based COVID-19 vaccine, which has secured full regulatory approval in the U.S. for adults aged 65 and older, as well as individuals 12 to 64 years old with specific elevated risk factors, providing a non-mRNA alternative. Its pipeline relies on a proprietary recombinant nanoparticle technology and the Matrix-M adjuvant. Important investigational programs feature a COVID-19-Influenza Combination vaccine and a standalone seasonal influenza vaccine, both advancing through Phase 3 clinical trials. Furthermore, a respiratory syncytial virus (RSV) F protein nanoparticle vaccine candidate remains under development. The company actively engages in strategic alliances, including a significant collaboration with Sanofi for the co-commercialization of Nuvaxovid and joint development of combination vaccines, and a partnership with Takeda for its COVID-19 vaccine in Japan. Novavax, Inc. was founded in 1987 and is based in Gaithersburg, Maryland.

Company News

Company News APIChatGPT

  • zacks.com

    Novavax (NVAX) Stock Declines While Market Improves: Some Information for Investors

  • defenseworld.net

    Novavax (NASDAQ:NVAX) Shares Down 9.1% – Here’s What Happened

  • reuters.com

    Novavax shareholder Shah Capital to step back from activist role

  • barrons.com

    Moderna and Novavax Stocks Slump as Biotech's Rally Takes a Breather

  • 247wallst.com

    Novavax Plunges 12% as Selloff Hits Vaccine Makers; Moderna Tumbles 10%, Pfizer Holds Steady

  • zacks.com

    Novavax (NVAX) Increases Despite Market Slip: Here's What You Need to Know

  • zacks.com

    Vaccine Stocks Rally on Reports of U.S.-led Push for Cancer Vaccines

  • 247wallst.com

    Novavax Soars 16%, Moderna Surges 11%, Merck Climbs 3% as Biotech Rallies

  • zacks.com

    Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know

  • defenseworld.net

    Novavax (NASDAQ:NVAX) Stock Jumps 10.5% – Should You Buy?

  • zacks.com

    Novavax (NVAX) Stock Sinks As Market Gains: Here's Why

  • benzinga.com

    Novavax Stock Falls Back: What's Going On?

  • 247wallst.com

    Novavax Pulls Back From Plague-Scare Spike as Officials Call Risk Low; Moderna Nudges Higher, Pfizer Inches Higher

  • zacks.com

    Novavax (NVAX) Surges 20.1%: Is This an Indication of Further Gains?

  • benzinga.com

    Novavax Shorts on Edge as Russia Plague Fears Spread

  • 247wallst.com

    Novavax Soars 22% as Sanofi Carries Nuvaxovid Into Vaccination Season; Moderna Climbs 8%, BioNTech Ticks Up

  • zacks.com

    Novavax (NVAX) Rises As Market Takes a Dip: Key Facts

  • zacks.com

    Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It

  • zacks.com

    Novavax (NVAX) Beats Stock Market Upswing: What Investors Need to Know

  • zacks.com

    Novavax (NVAX) Soars 7.0%: Is Further Upside Left in the Stock?